Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: Yahoo! Finance
Revenue exceeded analyst estimates by 136%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Looking ahead, revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 9.4% from a week ago. It is worth noting though that we have found 6 warning signs for Aprea Therapeutics (1 makes us a bit uncomfortable!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account o
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
APRE
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/8/24 - Form 8-K
- 11/8/24 - Form 424B5
- APRE's page on the SEC website